{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:37:09Z","timestamp":1794256629653,"version":"4.9.0"},"reference-count":195,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101342"],"award-info":[{"award-number":["82101342"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Horizontal research project","award":["02220141"],"award-info":[{"award-number":["02220141"]}]},{"name":"Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University.","id":[{"id":"https:\/\/ror.org\/053v2gh09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2021SK53501"],"award-info":[{"award-number":["2021SK53501"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson's disease (PD) is the second most common neurodegenerative disorder. PD patients exhibit varying degrees of abnormal glucose metabolism throughout disease stages. Abnormal glucose metabolism is closely linked to the PD pathogenesis and progression. Key glucose metabolism processes involved in PD include glucose transport, glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, the pentose phosphate pathway, and gluconeogenesis. Recent studies suggest that glucose metabolism is a potential therapeutic target for PD. In this review, we explore the connection between PD and abnormal glucose metabolism, focusing on the underlying pathophysiological mechanisms. We also summarize potential therapeutic drugs related to glucose metabolism based on results from current cellular and animal model studies.<\/jats:p>","DOI":"10.1186\/s40035-025-00467-8","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:00:46Z","timestamp":1739764846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Parkinson's disease and glucose metabolism impairment"],"prefix":"10.1186","volume":"14","author":[{"given":"Liangjing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-1557","authenticated-orcid":false,"given":"Hainan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet Lond Engl. 2021;397:2284\u2013303.","journal-title":"Lancet Lond Engl"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/genes13030471","volume":"13","author":"F Jia","year":"2022","unstructured":"Jia F, Fellner A, Kumar KR. Monogenic Parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes. 2022;13:471.","journal-title":"Genes"},{"issue":"2 Suppl 2","key":"467_CR3","first-page":"S30","volume":"51","author":"TN Chase","year":"1998","unstructured":"Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson\u2019s disease. Neurology. 1998;51(2 Suppl 2):S30-35.","journal-title":"Neurology"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1038\/s41467-024-49256-3","volume":"15","author":"WY Wani","year":"2024","unstructured":"Wani WY, Zunke F, Belur NR, Mazzulli JR. The hexosamine biosynthetic pathway rescues lysosomal dysfunction in Parkinson\u2019s disease patient iPSC derived midbrain neurons. Nat Commun. 2024;15:5206.","journal-title":"Nat Commun"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"16487","DOI":"10.1038\/s41598-024-65735-5","volume":"14","author":"J Nam","year":"2024","unstructured":"Nam J, Richie CT, Harvey BK, Voutilainen MH. Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson\u2019s disease. Sci Rep. 2024;14:16487.","journal-title":"Sci Rep"},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1152\/physrev.00062.2017","volume":"99","author":"GA Dienel","year":"2019","unstructured":"Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev. 2019;99:949\u20131045.","journal-title":"Physiol Rev"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","volume":"36","author":"P Mergenthaler","year":"2013","unstructured":"Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36:587.","journal-title":"Trends Neurosci"},{"key":"467_CR8","doi-asserted-by":"publisher","DOI":"10.1042\/AN20120021","volume":"4","author":"GA Dienel","year":"2012","unstructured":"Dienel GA. Fueling and imaging brain activation. ASN Neuro. 2012;4: e00093.","journal-title":"ASN Neuro"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nature01825","volume":"424","author":"NN Danial","year":"2003","unstructured":"Danial NN, Gramm CF, Scorrano L, Zhang C-Y, Krauss S, Ranger AM, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424:952\u20136.","journal-title":"Nature"},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2007.03.045","volume":"129","author":"A Colell","year":"2007","unstructured":"Colell A, Ricci J-E, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. 2007;129:983\u201397.","journal-title":"Cell"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","volume":"19","author":"JA Santiago","year":"2013","unstructured":"Santiago JA, Potashkin JA. Shared dysregulated pathways lead to Parkinson\u2019s disease and diabetes. Trends Mol Med. 2013;19:176\u201386.","journal-title":"Trends Mol Med"},{"key":"467_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/dc19-0760","volume":"43","author":"SY Rhee","year":"2020","unstructured":"Rhee SY, Han K-D, Kwon H, Park S-E, Park Y-G, Kim Y-H, et al. Association between glycemic status and the risk of Parkinson disease: a nationwide population-based study. Diabetes Care. 2020;43:2169\u201375.","journal-title":"Diabetes Care"},{"key":"467_CR13","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1002\/jcp.29682","volume":"235","author":"BL Tang","year":"2020","unstructured":"Tang BL. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol. 2020;235:7653\u201362.","journal-title":"J Cell Physiol"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/mds.23291","volume":"25","author":"LK Teune","year":"2010","unstructured":"Teune LK, Bartels AL, de Jong BM, Willemsen ATM, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395\u2013404.","journal-title":"Mov Disord"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9:149\u201358.","journal-title":"Lancet Neurol"},{"key":"467_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev. 2023;89: 101979.","journal-title":"Ageing Res Rev"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.3390\/ijms22115887","volume":"22","author":"R Han","year":"2021","unstructured":"Han R, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases-new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. Int J Mol Sci. 2021;22:5887.","journal-title":"Int J Mol Sci"},{"key":"467_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003549","volume":"95","author":"X Yue","year":"2016","unstructured":"Yue X, Li H, Yan H, Zhang P, Chang L, Li T. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine (Baltimore). 2016;95: e3549.","journal-title":"Medicine (Baltimore)"},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2021.06.002","volume":"89","author":"A S\u00e1nchez-G\u00f3mez","year":"2021","unstructured":"S\u00e1nchez-G\u00f3mez A, D\u00edaz Y, Duarte-Salles T, Compta Y, Mart\u00ed MJ. Prediabetes, type 2 diabetes mellitus and risk of Parkinson\u2019s disease: a population-based cohort study. Parkinsonism Relat Disord. 2021;89:22\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10654-023-00970-0","volume":"38","author":"D Aune","year":"2023","unstructured":"Aune D, Schlesinger S, Mahamat-Saleh Y, Zheng B, Udeh-Momoh CT, Middleton LT. Diabetes mellitus, prediabetes and the risk of Parkinson\u2019s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. Eur J Epidemiol. 2023;38:591\u2013604.","journal-title":"Eur J Epidemiol"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","volume":"34","author":"Q Xu","year":"2011","unstructured":"Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, et al. Diabetes and risk of Parkinson\u2019s disease. Diabetes Care. 2011;34:910\u20135.","journal-title":"Diabetes Care"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/dc11-1511","volume":"35","author":"Y Sun","year":"2012","unstructured":"Sun Y, Chang Y-H, Chen H-F, Su Y-H, Su H-F, Li C-Y. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012;35:1047\u20139.","journal-title":"Diabetes Care"},{"key":"467_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1212\/WNL.0b013e3182553cc9","volume":"78","author":"E Cereda","year":"2012","unstructured":"Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology. 2012;78:1507\u201311.","journal-title":"Neurology"},{"key":"467_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005921","volume":"96","author":"Y-W Yang","year":"2017","unstructured":"Yang Y-W, Hsieh T-F, Li C-I, Liu C-S, Lin W-Y, Chiang J-H, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore). 2017;96: e5921.","journal-title":"Medicine (Baltimore)"},{"key":"467_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/ane.12793","volume":"136","author":"E De Pablo-Fernandez","year":"2017","unstructured":"De Pablo-Fernandez E, Sierra-Hidalgo F, Benito-Le\u00f3n J, Bermejo-Pareja F. Association between Parkinson\u2019s disease and diabetes: data from NEDICES study. Acta Neurol Scand. 2017;136:732\u20136.","journal-title":"Acta Neurol Scand"},{"key":"467_CR26","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. 2018;91:e139\u201342.","journal-title":"Neurology"},{"key":"467_CR27","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano G, Polychronis S, Wilson H, Giordano B, Ferrara N, Niccolini F, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90:e1654\u201362.","journal-title":"Neurology"},{"key":"467_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","volume":"91","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Belete D, Bestwick J, Blauwendraat C, Bandres-Ciga S, Heilbron K, et al. Parkinson\u2019s disease determinants, prediction and gene-environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry. 2020;91:1046\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3233\/JPD-202486","volume":"11","author":"C Deischinger","year":"2021","unstructured":"Deischinger C, Dervic E, Kaleta M, Klimek P, Kautzky-Willer A. Diabetes mellitus is associated with a higher relative risk for Parkinson\u2019s disease in women than in men. J Parkinsons Dis. 2021;11:793\u2013800.","journal-title":"J Parkinsons Dis"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/mds.29122","volume":"37","author":"D Athauda","year":"2022","unstructured":"Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, et al. The impact of type 2 diabetes in Parkinson\u2019s disease. Mov Disord. 2022;37:1612\u201323.","journal-title":"Mov Disord"},{"key":"467_CR31","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s00415-022-11496-y","volume":"270","author":"G Pezzoli","year":"2023","unstructured":"Pezzoli G, Cereda E, Amami P, Colosimo S, Barichella M, Sacilotto G, et al. Onset and mortality of Parkinson\u2019s disease in relation to type II diabetes. J Neurol. 2023;270:1564\u201372.","journal-title":"J Neurol"},{"key":"467_CR32","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","volume":"19","author":"V Kotagal","year":"2013","unstructured":"Kotagal V, Albin RL, M\u00fcller MLTM, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord. 2013;19:522\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837\u201344.","journal-title":"Mov Disord"},{"key":"467_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.parkreldis.2014.10.008","volume":"20","author":"NI Bohnen","year":"2014","unstructured":"Bohnen NI, Kotagal V, M\u00fcller MLTM, Koeppe RA, Scott PJH, Albin RL, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord. 2014;20:1394\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jns.2008.08.029","volume":"276","author":"C Eggers","year":"2009","unstructured":"Eggers C, Hilker R, Burghaus L, Schumacher B, Heiss WD. High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson\u2019s disease. J Neurol Sci. 2009;276:27\u201330.","journal-title":"J Neurol Sci"},{"key":"467_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","volume":"58","author":"PT Meyer","year":"2017","unstructured":"Meyer PT, Frings L, R\u00fccker G, Hellwig S. 18F-FDG PET in Parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med. 2017;58:1888\u201398.","journal-title":"J Nucl Med"},{"key":"467_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10020-021-00301-7","volume":"27","author":"S Hirano","year":"2021","unstructured":"Hirano S. Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson\u2019s disease. Mol Med. 2021;27:40.","journal-title":"Mol Med"},{"key":"467_CR38","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1038\/s41598-019-48713-0","volume":"9","author":"M Devrome","year":"2019","unstructured":"Devrome M, Casteels C, Van der Perren A, Van Laere K, Baekelandt V, Koole M. Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson\u2019s disease using 18F-FDG PET imaging. Sci Rep. 2019;9:12368.","journal-title":"Sci Rep"},{"issue":"16 Pt 2","key":"467_CR39","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1212\/01.wnl.0000304050.05332.9c","volume":"70","author":"C Huang","year":"2008","unstructured":"Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16 Pt 2):1470\u20137.","journal-title":"Neurology"},{"key":"467_CR40","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp-2016-313918","volume":"88","author":"MJ Firbank","year":"2017","unstructured":"Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, et al. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson\u2019s disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88:310\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"467_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3233\/JPD-150583","volume":"5","author":"C Tard","year":"2015","unstructured":"Tard C, Demailly F, Delval A, Semah F, Defebvre L, Dujardin K, et al. Hypometabolism in posterior and temporal areas of the brain is associated with cognitive decline in Parkinson\u2019s disease. J Parkinsons Dis. 2015;5:569\u201374.","journal-title":"J Parkinsons Dis"},{"key":"467_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jns.2016.11.068","volume":"372","author":"T Baba","year":"2017","unstructured":"Baba T, Hosokai Y, Nishio Y, Kikuchi A, Hirayama K, Suzuki K, et al. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson\u2019s disease. J Neurol Sci. 2017;372:288\u201393.","journal-title":"J Neurol Sci"},{"key":"467_CR43","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/hbm.23080","volume":"37","author":"C Gasca-Salas","year":"2016","unstructured":"Gasca-Salas C, Clavero P, Garc\u00eda-Garc\u00eda D, Obeso JA, Rodr\u00edguez-Oroz MC. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson\u2019s disease patients with mild cognitive impairment. Hum Brain Mapp. 2016;37:968\u201377.","journal-title":"Hum Brain Mapp"},{"key":"467_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10020-021-00327-x","volume":"27","author":"SK Meles","year":"2021","unstructured":"Meles SK, Oertel WH, Leenders KL. Circuit imaging biomarkers in preclinical and prodromal Parkinson\u2019s disease. Mol Med Camb Mass. 2021;27:111.","journal-title":"Mol Med Camb Mass"},{"key":"467_CR45","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/mds.28592","volume":"36","author":"R Kim","year":"2021","unstructured":"Kim R, Lee J-Y, Kim YK, Kim H, Yoon EJ, Shin JH, et al. Longitudinal changes in isolated rapid eye movement sleep behavior disorder-related metabolic pattern expression. Mov Disord. 2021;36:1889\u201398.","journal-title":"Mov Disord"},{"key":"467_CR46","first-page":"302","volume":"10","author":"C-H Kim","year":"2022","unstructured":"Kim C-H, Jung J, Lee Y-U, Kim K-H, Kang S, Kang G-H, et al. Comparison of metabolites and gut microbes between patients with Parkinson\u2019s disease and healthy individuals-a pilot clinical observational study (STROBE Compliant). Healthc Basel Switz. 2022;10:302.","journal-title":"Healthc Basel Switz"},{"key":"467_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2147\/DMSO.S240728","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ouyang M, Gao X, Wang S, Fu C, Zeng J, et al. Phocea, pseudoflavonifractor and lactobacillus intestinalis: three potential biomarkers of gut microbiota that affect progression and complications of obesity-induced type 2 diabetes mellitus. Diabetes Metab Syndr Obes Targets Ther. 2020;13:835\u201350.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"467_CR48","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fmicb.2017.00214","volume":"8","author":"SS Bhute","year":"2017","unstructured":"Bhute SS, Suryavanshi MV, Joshi SM, Yajnik CS, Shouche YS, Ghaskadbi SS. Gut microbial diversity assessment of indian type-2-diabetics reveals alterations in eubacteria, archaea, and eukaryotes. Front Microbiol. 2017;8:214.","journal-title":"Front Microbiol"},{"key":"467_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.parkreldis.2018.05.026","volume":"55","author":"A Marques","year":"2018","unstructured":"Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, et al. Glucose dysregulation in Parkinson\u2019s disease: Too much glucose or not enough insulin? Parkinsonism Relat Disord. 2018;55:122\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmet.2011.05.008","volume":"14","author":"R Rodriguez-Diaz","year":"2011","unstructured":"Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, Berggren P-O, et al. Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab. 2011;14:45\u201354.","journal-title":"Cell Metab"},{"key":"467_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1586\/14737175.2015.1095093","volume":"15","author":"K Li","year":"2015","unstructured":"Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson\u2019s disease. Expert Rev Neurother. 2015;15:1189\u2013203.","journal-title":"Expert Rev Neurother"},{"key":"467_CR52","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","volume":"10","author":"JLY Cheong","year":"2020","unstructured":"Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ. The association between type 2 diabetes mellitus and Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:775.","journal-title":"J Parkinsons Dis"},{"key":"467_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0304-3940(96)12357-0","volume":"204","author":"M Takahashi","year":"1996","unstructured":"Takahashi M, Yamada T, Tooyama I, Moroo I, Kimura H, Yamamoto T, et al. Insulin receptor mRNA in the substantia nigra in Parkinson\u2019s disease. Neurosci Lett. 1996;204:201\u20134.","journal-title":"Neurosci Lett"},{"key":"467_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neuroscience.2014.04.006","volume":"270","author":"JK Morris","year":"2014","unstructured":"Morris JK, Vidoni ED, Perea RD, Rada R, Johnson DK, Lyons K, et al. Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience. 2014;270:139\u201347.","journal-title":"Neuroscience"},{"key":"467_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/jnc.13930","volume":"140","author":"KT Jones","year":"2017","unstructured":"Jones KT, Woods C, Zhen J, Antonio T, Carr KD, Reith MEA. Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain. J Neurochem. 2017;140:728\u201340.","journal-title":"J Neurochem"},{"key":"467_CR56","doi-asserted-by":"publisher","first-page":"pyv024","DOI":"10.1093\/ijnp\/pyv024","volume":"18","author":"MG Baladi","year":"2015","unstructured":"Baladi MG, Horton RE, Owens WA, Daws LC, France CP. Eating high fat chow decreases dopamine clearance in adolescent and adult male rats but selectively enhances the locomotor stimulating effects of cocaine in adolescents. Int J Neuropsychopharmacol. 2015;18:pyv024.","journal-title":"Int J Neuropsychopharmacol"},{"key":"467_CR57","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1038\/ncomms9543","volume":"6","author":"MA Stouffer","year":"2015","unstructured":"Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L, et al. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun. 2015;6:8543.","journal-title":"Nat Commun"},{"key":"467_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.12.029","volume":"109","author":"F Lopez Vicchi","year":"2016","unstructured":"Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016;109:74\u201380.","journal-title":"Pharmacol Res"},{"key":"467_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/mds.29298","volume":"38","author":"PW Cullinane","year":"2023","unstructured":"Cullinane PW, de Pablo FE, K\u00f6nig A, Outeiro TF, Jaunmuktane Z, Warner TT. Type 2 diabetes and Parkinson\u2019s disease: a focused review of current concepts. Mov Disord. 2023;38:162\u201377.","journal-title":"Mov Disord"},{"key":"467_CR60","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.3390\/ijms131012629","volume":"13","author":"K Shah","year":"2012","unstructured":"Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer\u2019s Disease. Int J Mol Sci. 2012;13:12629\u201355.","journal-title":"Int J Mol Sci"},{"key":"467_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"467_CR62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.molcel.2009.02.013","volume":"33","author":"S Gandhi","year":"2009","unstructured":"Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch K, et al. PINK1-associated Parkinson\u2019s disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell. 2009;33:627\u201338.","journal-title":"Mol Cell"},{"key":"467_CR63","doi-asserted-by":"publisher","first-page":"12425","DOI":"10.1074\/jbc.M114.625962","volume":"290","author":"AD Chaudhuri","year":"2015","unstructured":"Chaudhuri AD, Kabaria S, Choi DC, Mouradian MM, Junn E. MicroRNA-7 promotes glycolysis to protect against 1-methyl-4-phenylpyridinium-induced cell death. J Biol Chem. 2015;290:12425\u201334.","journal-title":"J Biol Chem"},{"key":"467_CR64","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1007\/s12035-016-9906-2","volume":"54","author":"A Anandhan","year":"2017","unstructured":"Anandhan A, Lei S, Levytskyy R, Pappa A, Panayiotidis MI, Cerny RL, et al. Glucose metabolism and AMPK signaling regulate dopaminergic cell death induced by gene (\u03b1-synuclein)-environment (paraquat) interactions. Mol Neurobiol. 2017;54:3825\u201342.","journal-title":"Mol Neurobiol"},{"key":"467_CR65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0169-328X(02)00487-4","volume":"107","author":"R Sankar","year":"2002","unstructured":"Sankar R, Thamotharan S, Shin D, Moley KH, Devaskar SU. Insulin-responsive glucose transporters-GLUT8 and GLUT4 are expressed in the developing mammalian brain. Brain Res Mol Brain Res. 2002;107:157\u201365.","journal-title":"Brain Res Mol Brain Res"},{"key":"467_CR66","first-page":"57","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2010;1:57\u201392.","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"467_CR67","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.21612","volume":"41","author":"E Sotiriou","year":"2010","unstructured":"Sotiriou E, Greene P, Krishna S, Hirano M, DiMauro S. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve. 2010;41:707\u201310.","journal-title":"Muscle Nerve"},{"key":"467_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41531-017-0014-4","volume":"3","author":"S Sakaue","year":"2017","unstructured":"Sakaue S, Kasai T, Mizuta I, Suematsu M, Osone S, Azuma Y, et al. Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism? NPJ Parkinsons Dis. 2017;3:13.","journal-title":"NPJ Parkinsons Dis"},{"key":"467_CR69","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al. Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J Clin Invest. 2019;129:4539\u201349.","journal-title":"J Clin Invest"},{"key":"467_CR70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0161-813X(02)00062-1","volume":"23","author":"JL Mazzola","year":"2002","unstructured":"Mazzola JL, Sirover MA. Alteration of intracellular structure and function of glyceraldehyde-3-phosphate dehydrogenase: a common phenotype of neurodegenerative disorders? Neurotoxicology. 2002;23:603\u20139.","journal-title":"Neurotoxicology"},{"key":"467_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.abb.2018.02.002","volume":"642","author":"K Barinova","year":"2018","unstructured":"Barinova K, Khomyakova E, Semenyuk P, Schmalhausen E, Muronetz V. Binding of alpha-synuclein to partially oxidized glyceraldehyde-3-phosphate dehydrogenase induces subsequent inactivation of the enzyme. Arch Biochem Biophys. 2018;642:10\u201322.","journal-title":"Arch Biochem Biophys"},{"key":"467_CR72","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1134\/S0006297920050090","volume":"85","author":"A Melnikova","year":"2020","unstructured":"Melnikova A, Pozdyshev D, Barinova K, Kudryavtseva S, Muronetz VI. \u03b1-Synuclein overexpression in SH-SY5Y human neuroblastoma cells leads to the accumulation of thioflavin S-positive aggregates and impairment of glycolysis. Biochem Biokhimiia. 2020;85:604\u201313.","journal-title":"Biochem Biokhimiia"},{"key":"467_CR73","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijbiomac.2019.01.064","volume":"127","author":"P Semenyuk","year":"2019","unstructured":"Semenyuk P, Barinova K, Muronetz V. Glycation of \u03b1-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase. Int J Biol Macromol. 2019;127:278\u201385.","journal-title":"Int J Biol Macromol"},{"key":"467_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2020.02.012","volume":"90","author":"T Schirinzi","year":"2020","unstructured":"Schirinzi T, Di Lazzaro G, Sancesario GM, Summa S, Petrucci S, Colona VL, et al. Young-onset and late-onset Parkinson\u2019s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging. 2020;90:119\u201324.","journal-title":"Neurobiol Aging"},{"key":"467_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105605","volume":"163","author":"J Li","year":"2022","unstructured":"Li J, Chen L, Qin Q, Wang D, Zhao J, Gao H, et al. Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson\u2019s disease. Neurobiol Dis. 2022;163: 105605.","journal-title":"Neurobiol Dis"},{"key":"467_CR76","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1038\/ncomms5514","volume":"5","author":"R Requejo-Aguilar","year":"2014","unstructured":"Requejo-Aguilar R, Lopez-Fabuel I, Fernandez E, Martins LM, Almeida A, Bola\u00f1os JP. PINK1 deficiency sustains cell proliferation by reprogramming glucose metabolism through HIF1. Nat Commun. 2014;5:4514.","journal-title":"Nat Commun"},{"key":"467_CR77","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ana.410350212","volume":"35","author":"Y Mizuno","year":"1994","unstructured":"Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson\u2019s disease. Ann Neurol. 1994;35:204\u201310.","journal-title":"Ann Neurol"},{"key":"467_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0197-0186(02)00225-5","volume":"43","author":"GE Gibson","year":"2003","unstructured":"Gibson GE, Kingsbury AE, Xu H, Lindsay JG, Daniel S, Foster OJF, et al. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson\u2019s disease. Neurochem Int. 2003;43:129\u201335.","journal-title":"Neurochem Int"},{"key":"467_CR79","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.410430121","volume":"43","author":"T Kobayashi","year":"1998","unstructured":"Kobayashi T, Matsumine H, Matuda S, Mizuno Y. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson\u2019s disease. Ann Neurol. 1998;43:120\u20133.","journal-title":"Ann Neurol"},{"key":"467_CR80","doi-asserted-by":"publisher","first-page":"7771","DOI":"10.1523\/JNEUROSCI.1842-04.2004","volume":"24","author":"L Tretter","year":"2004","unstructured":"Tretter L, Adam-Vizi V. Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. J Neurosci. 2004;24:7771\u20138.","journal-title":"J Neurosci"},{"key":"467_CR81","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/jnc.13836","volume":"139","author":"H Chen","year":"2016","unstructured":"Chen H, Denton TT, Xu H, Calingasan N, Beal MF, Gibson GE. Reductions in the mitochondrial enzyme \u03b1-ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental? J Neurochem. 2016;139:823\u201338.","journal-title":"J Neurochem"},{"key":"467_CR82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","volume":"208","author":"M Gerlach","year":"1991","unstructured":"Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson\u2019s disease. Eur J Pharmacol. 1991;208:273\u201386.","journal-title":"Eur J Pharmacol"},{"key":"467_CR83","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/ana.410360612","volume":"36","author":"VM Mann","year":"1994","unstructured":"Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, et al. Complex I, iron, and ferritin in Parkinson\u2019s disease substantia nigra. Ann Neurol. 1994;36:876\u201381.","journal-title":"Ann Neurol"},{"key":"467_CR84","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1523\/JNEUROSCI.0984-06.2006","volume":"26","author":"PM Keeney","year":"2006","unstructured":"Keeney PM, Xie J, Capaldi RA, Bennett JP. Parkinson\u2019s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006;26:5256\u201364.","journal-title":"J Neurosci"},{"key":"467_CR85","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/mds.10695","volume":"19","author":"M M\u00fcft\u00fcoglu","year":"2004","unstructured":"M\u00fcft\u00fcoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Og\u00fcs H, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord. 2004;19:544\u20138.","journal-title":"Mov Disord"},{"key":"467_CR86","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1074\/jbc.M710012200","volume":"283","author":"L Devi","year":"2008","unstructured":"Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283:9089\u2013100.","journal-title":"J Biol Chem"},{"key":"467_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial \u03b1-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486:235\u20139.","journal-title":"Neurosci Lett"},{"key":"467_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105344","volume":"157","author":"MZ Ali","year":"2022","unstructured":"Ali MZ, Dholaniya PS. Oxidative phosphorylation mediated pathogenesis of Parkinson\u2019s disease and its implication via Akt signaling. Neurochem Int. 2022;157: 105344.","journal-title":"Neurochem Int"},{"key":"467_CR89","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science. 2004;304:1158\u201360.","journal-title":"Science"},{"key":"467_CR90","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/emmm.200900006","volume":"1","author":"VA Morais","year":"2009","unstructured":"Morais VA, Verstreken P, Roethig A, Smet J, Snellinx A, Vanbrabant M, et al. Parkinson\u2019s disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol Med. 2009;1:99\u2013111.","journal-title":"EMBO Mol Med"},{"key":"467_CR91","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jnc.14683","volume":"150","author":"W Boonying","year":"2019","unstructured":"Boonying W, Joselin A, Huang E, Qu D, Safarpour F, Iyirhiaro GO, et al. Pink1 regulates FKBP5 interaction with AKT\/PHLPP and protects neurons from neurotoxin stress induced by MPP. J Neurochem. 2019;150:312\u201329.","journal-title":"J Neurochem"},{"key":"467_CR92","doi-asserted-by":"publisher","first-page":"11364","DOI":"10.1073\/pnas.0802076105","volume":"105","author":"CA Gautier","year":"2008","unstructured":"Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A. 2008;105:11364\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"467_CR93","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"CB L\u00fccking","year":"2000","unstructured":"L\u00fccking CB, D\u00fcrr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene. N Engl J Med. 2000;342:1560\u20137.","journal-title":"N Engl J Med"},{"key":"467_CR94","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.1074\/jbc.RA117.000499","volume":"293","author":"N Gigu\u00e8re","year":"2018","unstructured":"Gigu\u00e8re N, Pacelli C, Saumure C, Bourque M-J, Matheoud D, Levesque D, et al. Comparative analysis of Parkinson\u2019s disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons. J Biol Chem. 2018;293:9580\u201393.","journal-title":"J Biol Chem"},{"key":"467_CR95","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4161\/auto.6.7.13286","volume":"6","author":"S Geisler","year":"2010","unstructured":"Geisler S, Holmstr\u00f6m KM, Treis A, Skujat D, Weber SS, Fiesel FC, et al. The PINK1\/Parkin-mediated mitophagy is compromised by PD-associated mutations. Autophagy. 2010;6:871\u20138.","journal-title":"Autophagy"},{"key":"467_CR96","doi-asserted-by":"publisher","first-page":"18614","DOI":"10.1074\/jbc.M401135200","volume":"279","author":"JJ Palacino","year":"2004","unstructured":"Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem. 2004;279:18614\u201322.","journal-title":"J Biol Chem"},{"key":"467_CR97","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1756-6606-5-35","volume":"5","author":"Y Imaizumi","year":"2012","unstructured":"Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H, et al. Mitochondrial dysfunction associated with increased oxidative stress and \u03b1-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain. 2012;5:35.","journal-title":"Mol Brain"},{"key":"467_CR98","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1073\/pnas.0501282102","volume":"102","author":"RH Kim","year":"2005","unstructured":"Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A. 2005;102:5215\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"467_CR99","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2009.10.025","volume":"390","author":"T Hayashi","year":"2009","unstructured":"Hayashi T, Ishimori C, Takahashi-Niki K, Taira T, Kim Y, Maita H, et al. DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun. 2009;390:667\u201372.","journal-title":"Biochem Biophys Res Commun"},{"key":"467_CR100","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16:97\u2013107.","journal-title":"Nat Rev Neurol"},{"key":"467_CR101","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/hmg\/ddz271","volume":"29","author":"N Arbez","year":"2020","unstructured":"Arbez N, He X, Huang Y, Ren M, Liang Y, Nucifora FC, et al. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice. Hum Mol Genet. 2020;29:580\u201390.","journal-title":"Hum Mol Genet"},{"key":"467_CR102","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fneur.2020.00881","volume":"11","author":"S Delcambre","year":"2020","unstructured":"Delcambre S, Ghelfi J, Ouzren N, Grandmougin L, Delbrouck C, Seibler P, et al. Mitochondrial mechanisms of LRRK2 G2019S penetrance. Front Neurol. 2020;11:881.","journal-title":"Front Neurol"},{"issue":"Pt 8","key":"467_CR103","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/awu138","volume":"137","author":"S Bannwarth","year":"2014","unstructured":"Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain J Neurol. 2014;137(Pt 8):2329\u201345.","journal-title":"Brain J Neurol"},{"key":"467_CR104","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1212\/NXG.0000000000000276","volume":"4","author":"RG Lee","year":"2018","unstructured":"Lee RG, Sedghi M, Salari M, Shearwood A-MJ, Stentenbach M, Kariminejad A, et al. Early-onset Parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction. Neurol Genet. 2018;4:e276.","journal-title":"Neurol Genet"},{"key":"467_CR105","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.celrep.2015.08.001","volume":"12","author":"F-L Tang","year":"2015","unstructured":"Tang F-L, Liu W, Hu J-X, Erion JR, Ye J, Mei L, et al. VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep. 2015;12:1631\u201343.","journal-title":"Cell Rep"},{"key":"467_CR106","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.bbadis.2017.07.032","volume":"1863","author":"L Zhou","year":"2017","unstructured":"Zhou L, Wang W, Hoppel C, Liu J, Zhu X. Parkinson\u2019s disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim Biophys Acta Mol Basis Dis. 2017;1863:2791\u20135.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"467_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.205","volume":"4","author":"AC Costa","year":"2013","unstructured":"Costa AC, Loh SHY, Martins LM. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1\/parkin model of Parkinson\u2019s disease. Cell Death Dis. 2013;4: e467.","journal-title":"Cell Death Dis"},{"key":"467_CR108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050172","volume":"5","author":"JW Pridgeon","year":"2007","unstructured":"Pridgeon JW, Olzmann JA, Chin L-S, Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007;5: e172.","journal-title":"PLoS Biol"},{"key":"467_CR109","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/BJ20120509","volume":"447","author":"M Ogura","year":"2012","unstructured":"Ogura M, Yamaki J, Homma MK, Homma Y. Mitochondrial c-Src regulates cell survival through phosphorylation of respiratory chain components. Biochem J. 2012;447:281\u20139.","journal-title":"Biochem J"},{"key":"467_CR110","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1083\/jcb.200209098","volume":"160","author":"T Miyazaki","year":"2003","unstructured":"Miyazaki T, Neff L, Tanaka S, Horne WC, Baron R. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J Cell Biol. 2003;160:709\u201318.","journal-title":"J Cell Biol"},{"key":"467_CR111","doi-asserted-by":"publisher","first-page":"E1604","DOI":"10.1073\/pnas.1220659110","volume":"110","author":"S Yoshida","year":"2013","unstructured":"Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee M-J, Lee S, et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A. 2013;110:E1604-1612.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"467_CR112","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0161-813X(02)00110-9","volume":"24","author":"E Mazzio","year":"2003","unstructured":"Mazzio E, Soliman KFA. The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl 4-phenylpyridinium ion toxicity. Neurotoxicology. 2003;24:137\u201347.","journal-title":"Neurotoxicology"},{"key":"467_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164906","volume":"11","author":"D Kim","year":"2016","unstructured":"Kim D, Jeon H, Ryu S, Koo S, Ha K-T, Kim S. Proteomic analysis of the effect of Korean red ginseng in the striatum of a Parkinson\u2019s disease mouse model. PLoS ONE. 2016;11: e0164906.","journal-title":"PLoS ONE"},{"key":"467_CR114","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/mds.29333","volume":"38","author":"M Borsche","year":"2023","unstructured":"Borsche M, M\u00e4rtens A, H\u00f6rmann P, Br\u00fcckmann T, Lohmann K, Tunc S, et al. In vivo investigation of glucose metabolism in idiopathic and PRKN-related Parkinson\u2019s disease. Mov Disord. 2023;38:697\u2013702.","journal-title":"Mov Disord"},{"key":"467_CR115","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/s41467-019-10189-x","volume":"10","author":"E Haythorne","year":"2019","unstructured":"Haythorne E, Rohm M, van de Bunt M, Brereton MF, Tarasov AI, Blacker TS, et al. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic \u03b2-cells. Nat Commun. 2019;10:2474.","journal-title":"Nat Commun"},{"key":"467_CR116","first-page":"111","volume":"121","author":"S Abraham","year":"2005","unstructured":"Abraham S, Soundararajan CC, Vivekanandhan S, Behari M. Erythrocyte antioxidant enzymes in Parkinson\u2019s disease. Indian J Med Res. 2005;121:111\u20135.","journal-title":"Indian J Med Res"},{"key":"467_CR117","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","volume":"35","author":"L Dunn","year":"2014","unstructured":"Dunn L, Allen GF, Mamais A, Ling H, Li A, Duberley KE, et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson\u2019s disease. Neurobiol Aging. 2014;35:1111\u20135.","journal-title":"Neurobiol Aging"},{"key":"467_CR118","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12974-019-1659-1","volume":"16","author":"D Tu","year":"2019","unstructured":"Tu D, Gao Y, Yang R, Guan T, Hong J-S, Gao H-M. The pentose phosphate pathway regulates chronic neuroinflammation and dopaminergic neurodegeneration. J Neuroinflammation. 2019;16:255.","journal-title":"J Neuroinflammation"},{"key":"467_CR119","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1073\/pnas.0937239100","volume":"100","author":"D-C Wu","year":"2003","unstructured":"Wu D-C, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2003;100:6145\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"467_CR120","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.diabres.2007.01.037","volume":"77","author":"J Park","year":"2007","unstructured":"Park J, Chung J-J, Kim JB. New evaluations of redox regulating system in adipose tissue of obesity. Diabetes Res Clin Pract. 2007;77(Suppl 1):S11-16.","journal-title":"Diabetes Res Clin Pract"},{"key":"467_CR121","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000100903","volume":"44","author":"F Sanna","year":"2007","unstructured":"Sanna F, Bonatesta RR, Frongia B, Uda S, Banni S, Melis MP, et al. Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. J Vasc Res. 2007;44:253\u201363.","journal-title":"J Vasc Res"},{"key":"467_CR122","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1021\/cb400894a","volume":"9","author":"S Lei","year":"2014","unstructured":"Lei S, Zavala-Flores L, Garcia-Garcia A, Nandakumar R, Huang Y, Madayiputhiya N, et al. Alterations in energy\/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol. 2014;9:2032\u201348.","journal-title":"ACS Chem Biol"},{"key":"467_CR123","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1523\/JNEUROSCI.0122-06.2006","volume":"26","author":"R Mej\u00edas","year":"2006","unstructured":"Mej\u00edas R, Villadiego J, Pintado CO, Vime PJ, Gao L, Toledo-Aral JJ, et al. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci. 2006;26:4500\u20138.","journal-title":"J Neurosci"},{"key":"467_CR124","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.3390\/ijms22126568","volume":"22","author":"S Takahashi","year":"2021","unstructured":"Takahashi S. Neuroprotective function of high glycolytic activity in astrocytes: common roles in stroke and neurodegenerative diseases. Int J Mol Sci. 2021;22:6568.","journal-title":"Int J Mol Sci"},{"key":"467_CR125","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0301-0082(99)00060-X","volume":"62","author":"R Dringen","year":"2000","unstructured":"Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol. 2000;62:649\u201371.","journal-title":"Prog Neurobiol"},{"key":"467_CR126","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.410360305","volume":"36","author":"J Sian","year":"1994","unstructured":"Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al. Alterations in glutathione levels in Parkinson\u2019s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36:348\u201355.","journal-title":"Ann Neurol"},{"key":"467_CR127","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","volume":"20","author":"MK Herbert","year":"2014","unstructured":"Herbert MK, Eeftens JM, Aerts MB, Esselink RAJ, Bloem BR, Kuiperij HB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord. 2014;20:112\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR128","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000520302","volume":"21","author":"M Kaiserova","year":"2021","unstructured":"Kaiserova M, Chudackova M, Prikrylova Vranova H, Mensikova K, Kastelikova A, Stejskal D, et al. Cerebrospinal fluid levels of 5-hydroxyindoleacetic acid in Parkinson\u2019s disease and atypical parkinsonian syndromes. Neurodegener Dis. 2021;21:30\u20135.","journal-title":"Neurodegener Dis"},{"key":"467_CR129","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, et al. Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients. Mov Disord. 2017;32:1423\u201331.","journal-title":"Mov Disord"},{"key":"467_CR130","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D\u00f6ring F, Trenkwalder C, Schlossmacher MG. \u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230\u201340.","journal-title":"Lancet Neurol"},{"key":"467_CR131","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ane.12590","volume":"135","author":"AD Andersen","year":"2017","unstructured":"Andersen AD, Binzer M, Stenager E, Gramsbergen JB. Cerebrospinal fluid biomarkers for Parkinson\u2019s disease\u2014a systematic review. Acta Neurol Scand. 2017;135:34\u201356.","journal-title":"Acta Neurol Scand"},{"key":"467_CR132","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-020-00362-y","volume":"15","author":"H Lowes","year":"2020","unstructured":"Lowes H, Pyle A, Santibanez-Koref M, Hudson G. Circulating cell-free mitochondrial DNA levels in Parkinson\u2019s disease are influenced by treatment. Mol Neurodegener. 2020;15:10.","journal-title":"Mol Neurodegener"},{"key":"467_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094839","volume":"9","author":"K Burgos","year":"2014","unstructured":"Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer\u2019s and Parkinson\u2019s diseases correlate with disease status and features of pathology. PLoS ONE. 2014;9: e94839.","journal-title":"PLoS ONE"},{"key":"467_CR134","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/mds.27132","volume":"32","author":"J-P Trezzi","year":"2017","unstructured":"Trezzi J-P, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, et al. Distinct metabolomic signature in cerebrospinal fluid in early parkinson\u2019s disease. Mov Disord. 2017;32:1401\u20138.","journal-title":"Mov Disord"},{"key":"467_CR135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JPD-212936","volume":"12","author":"C Liguori","year":"2022","unstructured":"Liguori C, Stefani A, Fernandes M, Cerroni R, Mercuri NB, Pierantozzi M. Biomarkers of cerebral glucose metabolism and neurodegeneration in Parkinson\u2019s disease: a cerebrospinal fluid-based study. J Parkinsons Dis. 2022;12:537\u201344.","journal-title":"J Parkinsons Dis"},{"key":"467_CR136","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/01.jnen.0000179050.54522.5a","volume":"64","author":"E Dalf\u00f3","year":"2005","unstructured":"Dalf\u00f3 E, Portero-Ot\u00edn M, Ayala V, Mart\u00ednez A, Pamplona R, Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol. 2005;64:816\u201330.","journal-title":"J Neuropathol Exp Neurol"},{"key":"467_CR137","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0167-4943(95)00654-4","volume":"21","author":"J Barab\u00e1s","year":"1995","unstructured":"Barab\u00e1s J, Nagy E, Degrell I. Ascorbic acid in cerebrospinal fluid\u2014a possible protection against free radicals in the brain. Arch Gerontol Geriatr. 1995;21:43\u20138.","journal-title":"Arch Gerontol Geriatr"},{"key":"467_CR138","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508.","journal-title":"N Engl J Med"},{"issue":"35","key":"467_CR139","first-page":"473","volume":"1999","author":"F Blandini","year":"1998","unstructured":"Blandini F, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson\u2019s disease. Drugs Today (Barc). 1998;1999(35):473\u201383.","journal-title":"Drugs Today (Barc)"},{"issue":"21 Suppl 4","key":"467_CR140","first-page":"S1","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1-136.","journal-title":"Neurology"},{"key":"467_CR141","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1210\/me.2012-1226","volume":"26","author":"A Ustione","year":"2012","unstructured":"Ustione A, Piston DW. Dopamine synthesis and D3 receptor activation in pancreatic \u03b2-cells regulates insulin secretion and intracellular Ca2+ oscillations. Mol Endocrinol Baltim Md. 2012;26:1928\u201340.","journal-title":"Mol Endocrinol Baltim Md"},{"key":"467_CR142","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1210\/me.2013-1083","volume":"27","author":"A Ustione","year":"2013","unstructured":"Ustione A, Piston DW, Harris PE. Minireview: dopaminergic regulation of insulin secretion from the pancreatic islet. Mol Endocrinol. 2013;27:1198.","journal-title":"Mol Endocrinol"},{"key":"467_CR143","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000486252","volume":"45","author":"B-D Li","year":"2018","unstructured":"Li B-D, Cui J-J, Song J, Qi C, Ma P-F, Wang Y-R, et al. Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson\u2019s disease: a network meta-analysis. Cell Physiol Biochem. 2018;45:119\u201330.","journal-title":"Cell Physiol Biochem"},{"key":"467_CR144","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","volume":"21","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2007;21:677\u201392.","journal-title":"CNS Drugs"},{"key":"467_CR145","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/187221411794351842","volume":"5","author":"S Kalra","year":"2011","unstructured":"Kalra S, Kalra B, Agrawal N, Kumar S. Dopamine: the forgotten felon in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:61\u20135.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"467_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148536","volume":"1820","author":"\u0130 \u00dcnal","year":"2023","unstructured":"\u00dcnal \u0130, Cans\u0131z D, Beler M, Sezer Z, G\u00fczel E, Emekli-Alturfan E. Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson\u2019s disease model in zebrafish; mechanism involving ketogenesis and autophagy. Brain Res. 2023;1820: 148536.","journal-title":"Brain Res"},{"key":"467_CR147","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209805","volume":"103","author":"HK Kim","year":"2024","unstructured":"Kim HK, Biessels GJ, Yu MH, Hong N, Lee Y-H, Lee B-W, et al. SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology. 2024;103: e209805.","journal-title":"Neurology"},{"key":"467_CR148","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1111\/dom.15943","volume":"26","author":"J Guo","year":"2024","unstructured":"Guo J, Tang H, Shao H, Lu Y, Shi L, Fonseca VA, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes. Diabetes Obes Metab. 2024;26:5727\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"467_CR149","doi-asserted-by":"publisher","first-page":"147916412210981","DOI":"10.1177\/14791641221098168","volume":"19","author":"W-Z Siao","year":"2022","unstructured":"Siao W-Z, Lin T-K, Huang J-Y, Tsai C-F, Jong G-P. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: a nationwide population-based longitudinal cohort study. Diab Vasc Dis Res. 2022;19:14791641221098168.","journal-title":"Diab Vasc Dis Res"},{"key":"467_CR150","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.34067\/KID.0002772021","volume":"2","author":"EM Wright","year":"2021","unstructured":"Wright EM. SGLT2 Inhibitors: physiology and pharmacology. Kidney360. 2021;2:2027\u201337.","journal-title":"Kidney360"},{"key":"467_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8: 777861.","journal-title":"Front Med"},{"key":"467_CR152","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190\u20135.","journal-title":"Diabetes"},{"key":"467_CR153","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/jnr.490180407","volume":"18","author":"J Edmond","year":"1987","unstructured":"Edmond J, Robbins RA, Bergstrom JD, Cole RA, de Vellis J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J Neurosci Res. 1987;18:551\u201361.","journal-title":"J Neurosci Res"},{"key":"467_CR154","doi-asserted-by":"publisher","first-page":"25344","DOI":"10.1038\/srep25344","volume":"6","author":"CT Hong","year":"2016","unstructured":"Hong CT, Chau K-Y, Schapira AHV. Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Sci Rep. 2016;6:25344.","journal-title":"Sci Rep"},{"key":"467_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024954","volume":"9","author":"Q Shi","year":"2019","unstructured":"Shi Q, Liu S, Fonseca VA, Thethi TK, Shi L. Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. BMJ Open. 2019;9: e024954.","journal-title":"BMJ Open"},{"key":"467_CR156","doi-asserted-by":"publisher","first-page":"26438","DOI":"10.1073\/pnas.2009838117","volume":"117","author":"DE Mor","year":"2020","unstructured":"Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, et al. Metformin rescues Parkinson\u2019s disease phenotypes caused by hyperactive mitochondria. Proc Natl Acad Sci U S A. 2020;117:26438\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 3","key":"467_CR157","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607\u201314.","journal-title":"Biochem J"},{"key":"467_CR158","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-021-04059-0","volume":"599","author":"P Gonz\u00e1lez-Rodr\u00edguez","year":"2021","unstructured":"Gonz\u00e1lez-Rodr\u00edguez P, Zampese E, Stout KA, Guzman JN, Ilijic E, Yang B, et al. Disruption of mitochondrial complex I induces progressive Parkinsonism. Nature. 2021;599:650\u20136.","journal-title":"Nature"},{"key":"467_CR159","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13578-021-00700-7","volume":"11","author":"S Du","year":"2021","unstructured":"Du S, Zheng H. Role of FoxO transcription factors in aging and age-related metabolic and neurodegenerative diseases. Cell Biosci. 2021;11:188.","journal-title":"Cell Biosci"},{"key":"467_CR160","doi-asserted-by":"publisher","first-page":"1286838","DOI":"10.3389\/fendo.2023.1286838","volume":"14","author":"NA Teaney","year":"2023","unstructured":"Teaney NA, Cyr NE. FoxO1 as a tissue-specific therapeutic target for type 2 diabetes. Front Endocrinol. 2023;14:1286838.","journal-title":"Front Endocrinol"},{"key":"467_CR161","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1074\/jbc.M111.337907","volume":"287","author":"H Koh","year":"2012","unstructured":"Koh H, Kim H, Kim MJ, Park J, Lee H-J, Chung J. Silent information regulator 2 (Sir2) and Forkhead box O (FOXO) complement mitochondrial dysfunction and dopaminergic neuron loss in Drosophila PTEN-induced kinase 1 (PINK1) null mutant. J Biol Chem. 2012;287:12750\u20138.","journal-title":"J Biol Chem"},{"key":"467_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003412","volume":"9","author":"S Hwang","year":"2013","unstructured":"Hwang S, Song S, Hong YK, Choi G, Suh YS, Han SY, et al. Drosophila DJ-1 decreases neural sensitivity to stress by negatively regulating Daxx-like protein through dFOXO. PLoS Genet. 2013;9: e1003412.","journal-title":"PLoS Genet"},{"key":"467_CR163","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1093\/hmg\/ddq289","volume":"19","author":"T Kanao","year":"2010","unstructured":"Kanao T, Venderova K, Park DS, Unterman T, Lu B, Imai Y. Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet. 2010;19:3747\u201358.","journal-title":"Hum Mol Genet"},{"key":"467_CR164","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/hmg\/ddt530","volume":"23","author":"E Pino","year":"2014","unstructured":"Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria J-C, Knott GW, et al. FOXO3 determines the accumulation of \u03b1-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Hum Mol Genet. 2014;23:1435\u201352.","journal-title":"Hum Mol Genet"},{"key":"467_CR165","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/jpet.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry T, Lahiri DK, Chen D, Zhou J, Shaw KTY, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300:958\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"467_CR166","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1093\/brain\/awaa287","volume":"143","author":"E Bayram","year":"2020","unstructured":"Bayram E, Litvan I. Lowering the risk of Parkinson\u2019s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. Brain J Neurol. 2020;143:2868\u201371.","journal-title":"Brain J Neurol"},{"key":"467_CR167","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4212371","author":"E Hogg","year":"2022","unstructured":"Hogg E, Wu T, Bresee C, Wertheimer J, Malatt C, Tan E, et al. A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson\u2019s disease. SSRN Electron J. 2022. https:\/\/doi.org\/10.2139\/ssrn.4212371.","journal-title":"SSRN Electron J"},{"key":"467_CR168","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to J-L, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390:1176\u201385.","journal-title":"N Engl J Med"},{"key":"467_CR169","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the Exenatide-PD trial. JAMA Neurol. 2019;76:420\u20139.","journal-title":"JAMA Neurol"},{"key":"467_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102343","volume":"98","author":"KO Kopp","year":"2024","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Lahiri DK, Greig NH. Type 2 diabetes mellitus\/obesity drugs: A neurodegenerative disorders savior or a bridge too far? Ageing Res Rev. 2024;98: 102343.","journal-title":"Ageing Res Rev"},{"key":"467_CR171","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","volume":"36","author":"CK Wong","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, Koehler JA, Hammoud R, Rittig N, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36:130-143.e5.","journal-title":"Cell Metab"},{"key":"467_CR172","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047993","volume":"11","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson\u2019s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The \u201cExenatide-PD3\u201d study. BMJ Open. 2021;11: e047993.","journal-title":"BMJ Open"},{"key":"467_CR173","doi-asserted-by":"publisher","first-page":"1243132","DOI":"10.3389\/fendo.2023.1243132","volume":"14","author":"M Mei","year":"2023","unstructured":"Mei M, Liu M, Mei Y, Zhao J, Li Y. Sphingolipid metabolism in brain insulin resistance and neurological diseases. Front Endocrinol. 2023;14:1243132.","journal-title":"Front Endocrinol"},{"key":"467_CR174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172348","volume":"12","author":"RB Chan","year":"2017","unstructured":"Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, et al. Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: a lipidomic analysis. PLoS ONE. 2017;12: e0172348.","journal-title":"PLoS ONE"},{"key":"467_CR175","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/mds.28186","volume":"35","author":"K Klatt-Schreiner","year":"2020","unstructured":"Klatt-Schreiner K, Valek L, Kang J-S, Khlebtovsky A, Trautmann S, Hahnefeld L, et al. High glucosylceramides and low anandamide contribute to sensory loss and pain in Parkinson\u2019s disease. Mov Disord. 2020;35:1822\u201333.","journal-title":"Mov Disord"},{"key":"467_CR176","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","volume":"23","author":"B Kim","year":"2012","unstructured":"Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23:133.","journal-title":"Trends Endocrinol Metab"},{"key":"467_CR177","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1093\/brain\/awac176","volume":"145","author":"J Galper","year":"2022","unstructured":"Galper J, Dean NJ, Pickford R, Lewis SJG, Halliday GM, Kim WS, et al. Lipid pathway dysfunction is prevalent in patients with Parkinson\u2019s disease. Brain J Neurol. 2022;145:3472\u201387.","journal-title":"Brain J Neurol"},{"key":"467_CR178","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000480401","volume":"49","author":"TN Poly","year":"2017","unstructured":"Poly TN, Islam MM, Walther BA, Yang H-C, Nguyen P-A, Huang C-W, et al. Exploring the association between statin use and the risk of Parkinson\u2019s disease: a meta-analysis of observational studies. Neuroepidemiology. 2017;49:142\u201351.","journal-title":"Neuroepidemiology"},{"key":"467_CR179","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/nn1570","volume":"8","author":"B Liss","year":"2005","unstructured":"Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci. 2005;8:1742\u201351.","journal-title":"Nat Neurosci"},{"key":"467_CR180","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1124\/jpet.107.122036","volume":"322","author":"M Giustizieri","year":"2007","unstructured":"Giustizieri M, Cucchiaroni ML, Guatteo E, Bernardi G, Mercuri NB, Berretta N. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. J Pharmacol Exp Ther. 2007;322:721\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"467_CR181","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","volume":"17","author":"WG Ondo","year":"2011","unstructured":"Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson\u2019s disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17:156\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"467_CR182","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12883-022-02699-x","volume":"22","author":"S Kawashima","year":"2022","unstructured":"Kawashima S, Matsukawa N. RCIP-Nagoya Study Group Memantine for the patients with mild cognitive impairment in Parkinson\u2019s disease: a pharmacological fMRI study. BMC Neurol. 2022;22:175.","journal-title":"BMC Neurol"},{"key":"467_CR183","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s13104-018-3715-9","volume":"11","author":"R Imai","year":"2018","unstructured":"Imai R, Misaka S, Horita S, Yokota S, Ohashi R, Maejima Y, et al. Memantine has no effect on KATP channels in pancreatic \u03b2 cells. BMC Res Notes. 2018;11:614.","journal-title":"BMC Res Notes"},{"key":"467_CR184","doi-asserted-by":"publisher","first-page":"44120","DOI":"10.1038\/srep44120","volume":"7","author":"X-T Huang","year":"2017","unstructured":"Huang X-T, Li C, Peng X-P, Guo J, Yue S-J, Liu W, et al. An excessive increase in glutamate contributes to glucose-toxicity in \u03b2-cells via activation of pancreatic NMDA receptors in rodent diabetes. Sci Rep. 2017;7:44120.","journal-title":"Sci Rep"},{"key":"467_CR185","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm.3822","volume":"21","author":"J Marquard","year":"2015","unstructured":"Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med. 2015;21:363\u201372.","journal-title":"Nat Med"},{"key":"467_CR186","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/mp.2016.187","volume":"23","author":"S Moriguchi","year":"2018","unstructured":"Moriguchi S, Ishizuka T, Yabuki Y, Shioda N, Sasaki Y, Tagashira H, et al. Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer\u2019s disease therapy. Mol Psychiatry. 2018;23:211\u201321.","journal-title":"Mol Psychiatry"},{"key":"467_CR187","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ncl.2022.12.001","volume":"41","author":"R Patel","year":"2023","unstructured":"Patel R, Kompoliti K. Sex and gender differences in Parkinson\u2019s disease. Neurol Clin. 2023;41:371\u20139.","journal-title":"Neurol Clin"},{"key":"467_CR188","doi-asserted-by":"publisher","first-page":"21266","DOI":"10.1007\/s11356-020-11985-5","volume":"28","author":"M Makav","year":"2021","unstructured":"Makav M, Ero\u011flu HA. Recuperative effect of estrogen on rotenone-induced experimental model of Parkinson\u2019s disease in rats. Environ Sci Pollut Res Int. 2021;28:21266\u201375.","journal-title":"Environ Sci Pollut Res Int"},{"key":"467_CR189","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.freeradbiomed.2022.12.102","volume":"195","author":"R Yang","year":"2023","unstructured":"Yang R, Li J, Zhang J, Xue Q, Qin R, Wang R, et al. 17\u03b2-estradiol plays the anti-osteoporosis role via a novel ESR1-Keap1-Nrf2 axis-mediated stress response activation and Tmem119 upregulation. Free Radic Biol Med. 2023;195:231\u201344.","journal-title":"Free Radic Biol Med"},{"key":"467_CR190","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12964-022-00979-0","volume":"20","author":"L Tian","year":"2022","unstructured":"Tian L, Peng Y, Yang K, Cao J, Du X, Liang Z, et al. The ER\u03b1-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer. Cell Commun Signal CCS. 2022;20:178.","journal-title":"Cell Commun Signal CCS"},{"key":"467_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114279","volume":"182","author":"C-H Song","year":"2020","unstructured":"Song C-H, Kim N, Hee Nam R, In Choi S, Hee Son J, Eun YuJ, et al. 17\u03b2-Estradiol strongly inhibits azoxymethane\/dextran sulfate sodium-induced colorectal cancer development in Nrf2 knockout male mice. Biochem Pharmacol. 2020;182: 114279.","journal-title":"Biochem Pharmacol"},{"key":"467_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101142","volume":"45","author":"J Lee","year":"2021","unstructured":"Lee J, Walter MF, Korach KS, Noguchi CT. Erythropoietin reduces fat mass in female mice lacking estrogen receptor alpha. Mol Metab. 2021;45: 101142.","journal-title":"Mol Metab"},{"key":"467_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154846","volume":"123","author":"K Meneyrol","year":"2021","unstructured":"Meneyrol K, Est\u00e9vez-Salguero \u00c1, Gonz\u00e1lez-Garc\u00eda I, Guitton J, Taouis M, Benomar Y, et al. Ovarian insufficiency impairs glucose-stimulated insulin secretion through activation of hypothalamic de novo ceramide synthesis. Metabolism. 2021;123: 154846.","journal-title":"Metabolism"},{"key":"467_CR194","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41467-020-15982-7","volume":"11","author":"Y He","year":"2020","unstructured":"He Y, Xu P, Wang C, Xia Y, Yu M, Yang Y, et al. Estrogen receptor-\u03b1 expressing neurons in the ventrolateral VMH regulate glucose balance. Nat Commun. 2020;11:2165.","journal-title":"Nat Commun"},{"key":"467_CR195","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4014","volume":"42","author":"E Rymbai","year":"2024","unstructured":"Rymbai E, Sugumar D, Chakkittukandiyil A, Kothandan R, Selvaraj D. Molecular insights into the potential effects of selective estrogen receptor \u03b2 agonists in Alzheimer\u2019s and Parkinson\u2019s diseases. Cell Biochem Funct. 2024;42: e4014.","journal-title":"Cell Biochem Funct"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T12:24:52Z","timestamp":1739795092000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":195,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00467-8","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"27 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}